Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209189) titled 'Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Condition:
Head and Neck Cancer
Squamous Cell Carcinoma
Oral Cavity Cancer
Oropharyngeal Cancer
Laryngeal Cancer
Sinonasal Squamous Cell Carcinoma
HPV (Human Papillomavirus)-Associated Carcinoma
Skull Base Tumors
HPV 16 Po...